Publications

Do pancreatic cancer (PDA) stem cell markers predict biologic behavior?

IH Sahin, M Turkekul, M Capanu, G Askan, B McMahon, KH Yu, ...

Early Detection and Treatment Opportunities in Pancreatic Adenocarcinoma

EM O’Reilly

Expression levels of aldehyde dehydrogenase 1A1 (ALDH1A1) in circulating tumor and invasive cells (CTICs) as a biomarker for drug resistance and disulfiram in pancreatic …

M Ricigliano, B Cooper, AJ Ocean, H Tiriac, DA Tuveson, KH Yu, ...

Gemcitabine-related pneumonitis in pancreas adenocarcinoma—an infrequent event: elucidation of risk factors and management implications

IH Sahin, AI Geyer, DW Kelly, EM O'Reilly

Genetic diversity of pancreatic ductal adenocarcinoma and opportunities for precision medicine

ES Knudsen, EM O’Reilly, JR Brody, AK Witkiewicz

Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches

IH Sahin, MA Lowery, ZK Stadler, E Salo-Mullen, CA Iacobuzio-Donahue, ...

Genomic landscape of pancreatic adenocarcinoma: Does age matter?

I Ben-Aharon, M Elkabets, R Pelossof, KH Yu, PJ Allen, ...

Genomic profiling of pancreas ductal adenocarcinoma (PDA), actionability, and correlation with clinical phenotype.

E Jordan, MA Lowery, R Ptashkin, A Zehir, MF Berger, H Maynard, ...

Identification of potentially actionable molecular alterations in advanced hepatocellular carcinoma (HCC).

JJ Harding, ZJ Heins, LC Connell, T Soumerai, NE Kemeny, WR Jarnagin, ...

Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB …

AP Venook, D Niedzwiecki, F Innocenti, B Fruth, C Greene, BH O'Neil, ...

Integrated patient-derived models delineate individualized therapeutic vulnerabilities of pancreatic cancer

AK Witkiewicz, U Balaji, C Eslinger, E McMillan, W Conway, B Posner, ...

Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer

S Prasad, L Cambridge, F Huguet, JF Chou, Z Zhang, AJ Wu, EM O’Reilly, ...

Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?

MY Teo, EM O’Reilly

Management of metastatic pancreatic adenocarcinoma

AR Cheema, EM O’Reilly

Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline

DPS Sohal, PB Mangu, AA Khorana, MA Shah, PA Philip, EM O’Reilly, ...

Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy

IH Sahin, CA Iacobuzio-Donahue, EM O’Reilly

Oxaliplatin neurotoxicity has a spectrum of manifestations from an often reversible acute neurotoxicity to a more irreversible “stocking and glove” chronic neuropathy that is …

IH Sahin, AI Geyer, DW Kelly, EM O'Reilly

Pancreas adenocarcinoma: ascites, clinical manifestations, and management implications

AM Hicks, J Chou, M Capanu, MA Lowery, KH Yu, EM O'Reilly

Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer

AD Rao, EA Sugar, DT Chang, KA Goodman, A Hacker-Prietz, LM Rosati, ...

Phase 1B trial of ADI-PEG 20 (A) plus nab-Paclitaxel (nab-P) and gemcitabine (gem) in subjects with advanced pancreatic cancer (APC).

MA Lowery, M Capanu, DC Glassman, CM Covington, J Gluskin, ...

Phase I trial of HuMab-5B1 (MVT-5873), a novel monoclonal antibody targeting sLea, in patients with advanced pancreatic cancer and other CA19-9 positive malignancies

EM O'Reilly, TM Bauer, J Infante, JC Gutheil, P Klein, KH Yu, MA Lowery, ...

Presentation, clinical behavior, outcomes and therapies for patients with advanced pancreas adenocarcinoma (PAC) who present with or develop ascites.

A Mier Hicks, EM O'Reilly, M Capanu, MA Lowery, KH Yu

ReCAP: hospitalizations in older adults with advanced cancer: the role of chemotherapy

CB O’Neill, CL Atoria, EM O’Reilly, MC Henman, PB Bach, EB Elkin, ...

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer …

EM O'Reilly, D Mahalingam, JM Roach, PJ Miller, ME Rosano, S Krause, ...

Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.

MA Lowery, LW Goff, E Jordan, R Wang, AG Bocobo, JF Chou, ...

Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.

LW Goff, MA Lowery, E Jordan, R Wang, AG Bocobo, JF Chou, ...

Texture analysis for survival prediction of pancreatic ductal adenocarcinoma patients with neoadjuvant chemotherapy

J Chakraborty, L Langdon-Embry, JG Escalon, PJ Allen, MA Lowery, ...

Weight loss, diabetes, fatigue, and depression preceding pancreatic cancer

SH Olson, Y Xu, K Herzog, A Saldia, EM DeFilippis, P Li, PJ Allen, ...

Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas

LH Tang, BR Untch, DL Reidy, E O'Reilly, D Dhall, L Jih, O Basturk, ...

Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas (vol 22 …

LH Tang, BR Untch, DL Reidy, E O'Reilly, D Dhall, L Jih

‘We have to discuss it’: cancer patients' advance care planning impressions following educational information about cardiopulmonary resuscitation

AS Epstein, E Shuk, EM O'reilly, KA Gary, AE Volandes

“Months, not years”: Impact of clinical discussions of advanced cancer life-expectancy on patient illness understanding.

AS Epstein, HG Prigerson, L Saltz, EM O'Reilly, MA Shah, PK Maciejewski

“This is not me”: patient, family, cultural and clinician considerations in cases of severe cancer-related debility

D Li, GK Abou-Alfa, AD Viny, M Cammarata, A Shamseddine, A Al-Olayan, ...

90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies

VJ Picozzi, RK Ramanathan, MA Lowery, AJ Ocean, EP Mitchel, ...

A phase I trial of binimetinib in combination with gemcitabine (G) and cisplatin (C) patients (pts) with untreated advanced biliary cancer (ABC).

MA Lowery, EM O'Reilly, JJ Harding, E Salehi, E Hollywood, M Bradley, ...

Abstract B98: Final results of a randomized phase Ib study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having at least two prior …

VJ Picozzi, RK Ramanathan, MA Lowery, AJ Ocean, EP Mitchell, ...

Abstract IA28: BRCA-mutated pancreas adenocarcinoma: Emerging therapeutic implications

EM O'Reilly

Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma

D Li, EM O’Reilly

Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance).

JM Clarke, H Pang, MD Starr, AJ Hatch, HL Kindler, EM O'Reilly, ...

EBV-associated lymphoepithelioma-like carcinoma of the pancreas: case report with targeted sequencing analysis

RT Samdani, JF Hechtman, E O'Reilly, R DeMatteo, CS Sigel

Final results of a randomized phase Ib study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having at least two prior therapies

VJ Picozzi, RK Ramanathan, MA Lowery, AJ Ocean, EP Mitchell, ...

Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+ Gem) in …

EM O'Reilly, LS Smith, JC Bendell, JH Strickler, M Zalupski, W Gluck, ...

FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma

E Sadot, A Doussot, EM O’Reilly, MA Lowery, KA Goodman, RKG Do, ...

Hepatocellular carcinoma (HCC) and bone metastases (Mets).

JJ Harding, G Abu Zeinah, JF Chou, DH Owen, M Ly, MA Lowery, ...

Identification of germline genetic mutations in patients with pancreatic cancer

EE Salo‐Mullen, EM O'Reilly, DP Kelsen, AM Ashraf, MA Lowery, KH Yu, ...

Intensity-modulated radiation therapy (IMRT) in patients with locally advanced pancreatic cancer (LAPC).

C Hajj, F Huguet, AJC Wu, EM O'Reilly, C Winston, DL Reidy, PJ Allen, ...

Intrahepatic cholangiocarcinoma: expert consensus statement

SM Weber, D Ribero, EM O'Reilly, N Kokudo, M Miyazaki, TM Pawlik

JANUS 2: A phase III study of survival, tumor response, and symptom response with ruxolitinib plus capecitabine or placebo plus capecitabine in patients with advanced or …

EM O'Reilly, C Walker, J Clark, KJ Brill, FW Dawkins, JC Bendell

Liver resection for metastatic colorectal leiomyosarcoma: a single center experience

W Faraj, J El-Kehdy, G El Nounou, S Deeba, H Fakih, M Jabbour, ...

Liver-directed conversion therapy in metastatic colon cancer

A Snyder, N Kemeny, A Shamseddine, A Al-Olayan, F El-Merhi, ...